CryoCath says additional data on Artic Front catheter shows 100% success

By E. Janene Geiss

Philadelphia, April 24 - CryoCath Technologies Inc. said Monday that additional data on the company's proprietary Arctic Front catheter to treat atrial fibrillation showed 100% acute success.

Following ablation procedures on 39 patients, all cases were considered successful with complete isolation of all pulmonary veins, of which 90% were isolated using only the Artic Front, according to a company news release.

Another 45 patients also received 100% acute success following ablation with complete electrical isolation of all pulmonary veins, of which about 70% were isolated using only Artic Front, officials said.

The data was presented at the German Cardiac Society's annual conference in Mannheim, Germany, on Saturday, officials said.

For 25 patients, 80% were atrial-fibrillation free three to six months after treatments. Fifteen were atrial-fibrillation free after only one procedure and five following a second procedure that involved minimal vein touch-up. The rest of the group have all experienced a clinically reduced atrial-fibrillation burden and do not require further treatment, officials said.

The Arctic Front catheter was designed to treat atrial fibrillation. This bi-directional balloon catheter enables physicians to isolate all four pulmonary veins and create large, durable transmural lesions that stop the incidence of atrial fibrillation episodes.

CryoCath is a Montreal, Quebec, medical technology company that develops cryotherapy products to treat cardiovascular disease.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.